Cytokine and neurotransmitter regulation of glial cell production of Il-6; indications for neurodegenerative disorders
type: CreativeWork
description: The cytokines interleukin-1 (IL-1) and interleukin-6 (IL-6) are produced during an immune reaction and cause inflammation and swelling of the surrounding tissue. AD is a neurodegenerative disorder characterized by well-defined neuropathologic entities. Both IL-1 and IL-6 are present in senile plaques and may cause a self-propagating inflammatory process that contributes to the disease processes of AD; Somatostatin (SRIF) is a small, inhibitory neuropeptide present throughout the CNS. Because SRIF is an inhibitory neuropeptide we sought to determine the effects of SRIF on the production of IL-6 in rat C6 glial tumor cells. The release of IL-6 in the C6 cell conditioned media was quantified using the IL-6 dependent 7TD1 hybridoma bioassay; We decided to investigate GABA ability to inhibit the release of IL-6 by IL-1beta; To better understand the signal pathways of IL-1beta that results in the release of IL-6 we used the inhibitors SP600125 and SB203580. SB203580 is a p38 MAPK inhibitor that targets the p38alpha and p38beta2 kinases, while the p38beta kinase exhibits only partially sensitivity. The inhibitor SP600125 targets the JNK kinase. (Abstract shortened by UMI.).
abstract: The cytokines interleukin-1 (IL-1) and interleukin-6 (IL-6) are produced during an immune reaction and cause inflammation and swelling of the surrounding tissue. AD is a neurodegenerative disorder characterized by well-defined neuropathologic entities. Both IL-1 and IL-6 are present in senile plaques and may cause a self-propagating inflammatory process that contributes to the disease processes of AD; Somatostatin (SRIF) is a small, inhibitory neuropeptide present throughout the CNS. Because SRIF is an inhibitory neuropeptide we sought to determine the effects of SRIF on the production of IL-6 in rat C6 glial tumor cells. The release of IL-6 in the C6 cell conditioned media was quantified using the IL-6 dependent 7TD1 hybridoma bioassay; We decided to investigate GABA ability to inhibit the release of IL-6 by IL-1beta; To better understand the signal pathways of IL-1beta that results in the release of IL-6 we used the inhibitors SP600125 and SB203580. SB203580 is a p38 MAPK inhibitor that targets the p38alpha and p38beta2 kinases, while the p38beta kinase exhibits only partially sensitivity. The inhibitor SP600125 targets the JNK kinase. (Abstract shortened by UMI.).
author: Horrell, Donald Scott
language: English
date published: 2002-01-01T08:00:00Z
date modified: 2026-07-24T05:25:33Z
provider: University of Nevada - Las Vegas
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: University of Nevada, Las Vegas

PropertyValue
property ID: DOI
value: 10.25669/pe3a-dy5y